Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation and expansion study of KK2260 in advanced solid tumors and squamous cell carcinomas of the esophagus or head and neck
jRCT2031230372Phase 1Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Nov 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of KK2260 in Nonhematologic neoplasms, Esophageal Squamous Cell Carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Kyowa Kirin. Primary endpoints: Dose-limiting toxicity, Adverse events and 5 more. Started Nov 2023; status: recruiting.
02
Drugs
KK2260
03
Conditions
Nonhematologic neoplasmsEsophageal Squamous Cell Carcinoma (ESCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031230372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230372.